Vir Biotechnology
Vir Biotechnology Raises $250M in Series E
Vir Biotechnology Raises $250M in Series E
Vir Biotechnology has successfully raised $250M in a Series E at a $3.3B valuation led by SoftBank Vision Fund, Arch Venture Partners, ARCH Venture Partners, Intermediate Capital Group.
Company Overview
Vir Biotechnology is a Biotech company headquartered in 499 Illinois Street, San Francisco, CA 94158, founded in 2016 with 500+ employees.
Infectious disease treatment development
Fundraising Details
- Amount Raised: $250M
- Round Type: Series E
- Valuation: $3.3B
- Date: 2024-01-29
- Investors: SoftBank Vision Fund, Arch Venture Partners, ARCH Venture Partners, Intermediate Capital Group
About Vir Biotechnology
Infectious disease treatment development The company is positioned in the Biotech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: 499 Illinois Street, San Francisco, CA 94158
- Founded: 2016
- Team Size: 500+
- Industry: Biotech
What This Means
This funding round demonstrates strong investor confidence in Vir Biotechnology's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Vir Biotechnology's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $3.3B valuation marks an important milestone for Vir Biotechnology, positioning the company among notable players in the Biotech industry.
Looking Ahead
With this new capital, Vir Biotechnology is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2024-01-29. For more information about Vir Biotechnology, visit their headquarters at 499 Illinois Street, San Francisco, CA 94158.
Company Info
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started